PEP

post-exposure prophylaxis

ABSTRACTBACKGROUNDThis study has assessed a new Anti-COVID-19 Monoclonal Antibody Nasal Spray (SA58) for post-exposure prophylaxis (PEP) against symptomatic coronavirus disease 2019 (COVID-19).METHODSWe conducted an efficacy study in adults aged 18 years and older within three days of exposure to a SARS-CoV-2 infected individual.

21 lineages of SARS-CoV-2 variants were identified, and all were the Omicron variant BF·7.INTERPRETATIONSA58 Nasal Spray showed favorable efficacy and safety in preventing SARS-CoV-2 infection or symptomatic COVID-19 in healthy adult workers who had exposure to SARS-CoV-2 within 72 hours.FUNDINGNo funding was received for this study.Research in contextEvidence before this studyMonoclonal antibodies (mAbs) and the post-exposure prophylaxis (PEP) with mAbs represent a very important public health strategy against COVID-19 outbreak.

AbstractThe efficacy of Hydroxychloroquine (HCQ) as post-exposure prophylaxis (PEP) for the prevention of COVID-19 was contentious.